Mark Vannorsdall, MD
Nephrology · Pensacola, FLNPI 1336141555
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 71.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $6,660 and has fallen 94.0% since, to $400 in 2025. Among nephrology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $58.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Otsuka America Pharmaceutical, Inc.$419
- Amgen$360
- Aurinia Pharma U.S., Inc.$342
- Vifor Pharma, Inc.$195
- Bayer$191
- plus $1K from 17 others
Across 1 payment — averaging $2068.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2K
What the payments were for
- Speaking & faculty fees$5,85059%
- Travel & lodging$1301%
- Food & beverage$3,88839%
- Education$701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 44 | $7,104 |
| Otsuka America Pharmaceutical, Inc. | 21 | $419 |
| Amgen(2 entities) | 15 | $360 |
| Aurinia Pharma U.S., Inc. | 12 | $342 |
| Vifor Pharma, Inc. | 11 | $195 |
| Bayer | 10 | $191 |
| OPKO Pharmaceuticals, LLC | 6 | $185 |
| Akebia Therapeutics Inc | 8 | $150 |
| Travere Therapeutics, Inc. | 7 | $148 |
| Novartis | 4 | $109 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $109 |
| Bard Peripheral Vascular, Inc. | 1 | $97 |
| Fresenius USA Marketing, Inc. | 6 | $97 |
| Calliditas Therapeutics US Inc. | 4 | $92 |
| Angiodynamics, Inc. | 3 | $91 |
| Ardelyx, Inc. | 2 | $54 |
| Lilly USA, LLC | 3 | $52 |
| Mallinckrodt Hospital Products Inc. | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,937 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 144 | $98,244 |
| JardianceEmpagliflozin | 42 | $36,816 |
| KerendiaFinerenone | 14 | $12,151 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $8,074 |
| Lanthanum Carbonate | 13 | $6,610 |
| Losartan Potassium | 247 | $2,537 |
| Clonidine | 14 | $1,948 |
| Potassium Chloride | 76 | $1,910 |
| Potassium Citrate ErPotassium Citrate | 13 | $1,627 |
| Furosemide | 188 | $1,400 |
| Amlodipine Besylate | 184 | $1,330 |
| Chlorthalidone | 76 | $1,211 |
| Minoxidil | 11 | $1,124 |
| Lisinopril | 112 | $1,032 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 27 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $7,104 | $106,318155 claims |
| BayerKerendia | $191 | $12,15114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.
Other nephrology in Pensacola
- Nicholas NagraniPensacola$30K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.